Essential Updates 2023/2024: Minimally Invasive Surgery for Biliary Tract Cancer

Abstract

Minimally invasive surgery (MIS) for biliary tract cancer (BTC) has gained traction with advancements in laparoscopic and robotic techniques. However, its oncological impact remains uncertain. This review highlights key studies from 2023 and 2024 on MIS for BTC, including distal bile duct, hilar bile duct, gallbladder, and intrahepatic bile duct cancer. Although feasibility and safety are supported in experienced centers, long-term prognostic equivalence to open surgery remains debatable. Further studies are required to clarify surgical and oncological outcomes.